Articles related to ADVERSE EVENTS

In a randomized trial of 1,412 patients with acute ischemic stroke, reteplase was more likely to result in excellent functional outcomes at 90 days compared to alteplase.

A recent phase 3 trial demonstrates that a combination therapy of belantamab mafodotin, bortezomib, and dexamethasone leads to significantly longer progression-free survival in patients with relapsed or refractory multiple myeloma compared to a regimen including daratumumab.

Several medications, including antihistamines, muscle relaxers, and benzodiazepines, are known to cause fatigue. Understanding these effects and managing patient expectations can help mitigate this common side effect.

MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

A case of pacemaker-lead dislodgement with cardiac perforation in a 96-year-old patient highlights the importance of recognizing and addressing complications swiftly to prevent severe outcomes.